Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PHAT Phathom Pharmaceuticals

Not Yet Opened 03-02 16:00:00 EST

11.46

-1.10

-8.76%

盘后11.45

-0.01-0.09%

19:23 EST

High12.33	Low11.44	Vol1.95M
Open12.12	D1 Closing12.56	Amplitude7.13%
Mkt Cap903.03M	Tradable Cap659.72M	Total Shares78.80M
T/O23.21M	T/O Rate3.39%	Tradable Shares57.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PHAT","market":"US","secType":"STK","nameCN":"Phathom Pharmaceuticals","latestPrice":11.46,"timestamp":1772485200000,"preClose":12.56,"halted":0,"volume":1950301,"hourTrading":{"tag":"盘后","latestPrice":11.45,"preClose":11.46,"latestTime":"19:23 EST","volume":14283,"amount":163673.31,"timestamp":1772497420819,"change":-0.01,"changeRate":-0.000873,"amplitude":0.000873},"delay":0,"changeRate":-0.08757961783439487,"floatShares":57566899,"shares":78798712,"eps":-3.034157,"marketStatus":"Not Yet Opened","change":-1.1,"latestTime":"03-02 16:00:00 EST","open":12.12,"high":12.33,"low":11.435,"amount":23214809.211093,"amplitude":0.071258,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.034157,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1772528400000},"marketStatusCode":0,"adr":0,"listingDate":1571976000000,"exchange":"NASDAQ","adjPreClose":12.56,"preHourTrading":{"tag":"盘前","latestPrice":12.13,"preClose":12.56,"latestTime":"09:29 EST","volume":347389,"amount":4354077.499247,"timestamp":1772461799999,"change":-0.43,"changeRate":-0.034236,"amplitude":0.124204},"postHourTrading":{"tag":"盘后","latestPrice":11.45,"preClose":11.46,"latestTime":"19:23 EST","volume":14283,"amount":163673.31,"timestamp":1772497420819,"change":-0.01,"changeRate":-0.000873,"amplitude":0.000873},"volumeRatio":1.477926,"impliedVol":0.6124,"impliedVolPercentile":0.0876},"requestUrl":"/m/hq/s/PHAT/tweets","defaultTab":"tweets","newsList":[{"id":"2614286857","title":"Phathom Pharmaceuticals Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2614286857","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614286857?lang=en_us&edition=fundamental","pubTime":"2026-02-27 23:58","pubTimestamp":1772207880,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/PHAT/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 27, 2026 10:58 ET (15:58 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2614787853","title":"Phathom Pharmaceuticals price target raised to $25 from $20 at Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2614787853","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614787853?lang=en_us&edition=fundamental","pubTime":"2026-02-27 20:39","pubTimestamp":1772195953,"startTime":"0","endTime":"0","summary":"Guggenheim raised the firm’s price target on Phathom Pharmaceuticals (PHAT) to $25 from $20 and keeps a Buy rating on the shares. The firm, which c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-price-target-raised-to-25-from-20-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/phathom-pharmaceuticals-price-target-raised-to-25-from-20-at-guggenheim-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"2614085880","title":"Phathom Pharmaceuticals: Early VOQUEZNA Traction, Strengthened Balance Sheet, and Clear Path to Profitability Support Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2614085880","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614085880?lang=en_us&edition=fundamental","pubTime":"2026-02-27 19:55","pubTimestamp":1772193330,"startTime":"0","endTime":"0","summary":"Matthew Caufield, an analyst from H.C. Wainwright, reiterated the Buy rating on Phathom Pharmaceuticals. The associated price target remains the sa...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/phathom-pharmaceuticals-early-voquezna-traction-strengthened-balance-sheet-and-clear-path-to-profitability-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/phathom-pharmaceuticals-early-voquezna-traction-strengthened-balance-sheet-and-clear-path-to-profitability-support-buy-rating-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT"],"gpt_icon":0},{"id":"2614078925","title":"Analysts’ Top Healthcare Picks: Phathom Pharmaceuticals (PHAT), Certara (CERT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614078925","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614078925?lang=en_us&edition=fundamental","pubTime":"2026-02-27 03:20","pubTimestamp":1772133610,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Phathom Pharmaceuticals (PHAT – Research Report) and...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-phathom-pharmaceuticals-phat-certara-cert-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-top-healthcare-picks-phathom-pharmaceuticals-phat-certara-cert-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4167","PHAT","LABU","XLV","BK4588","CERT","HCSG","LU0029874061.USD","LU0128526141.USD","BK4581","XBI","BK4585","BK4007"],"gpt_icon":0},{"id":"2614021397","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), BioLife Solutions (BLFS) and RxSight (RXST)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614021397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614021397?lang=en_us&edition=fundamental","pubTime":"2026-02-27 00:20","pubTimestamp":1772122811,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Phathom Pharmaceuticals (PHAT – Research Report), ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-phathom-pharmaceuticals-phat-biolife-solutions-blfs-and-rxsight-rxst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-phathom-pharmaceuticals-phat-biolife-solutions-blfs-and-rxsight-rxst-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","LU0128526141.USD","BK4198","LU0029874061.USD","BK4121","PHAT","LU1169589451.USD","BK4539","XLV","BK4007","BK4588","LU1169590202.USD","XBI","BLFS","BK4585","LABU","BK4581","RXST","HCSG"],"gpt_icon":0},{"id":"2614879049","title":"Phathom Pharmaceuticals Q4 revenue slightly beats expectations","url":"https://stock-news.laohu8.com/highlight/detail?id=2614879049","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614879049?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:25","pubTimestamp":1772108749,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Q4 revenue slightly beats expectationsOverviewBiopharmaceutical firm's Q4 revenue slightly beat analyst expectationsCompany reduced Q4 net loss compared to previous yearStrengt","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nL1N3ZM0LR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2614504528","title":"Phathom posts FY 2025 net revenues of USD 175.1 million, up 217%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614504528","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614504528?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:03","pubTimestamp":1772107429,"startTime":"0","endTime":"0","summary":"Phathom posts FY 2025 net revenues of USD 175.1 million, up 217%               Phathom reported Q4 2025 net revenues of USD 57.6 million and FY 2025 net revenues of USD 175.1 million (up 217% YoY). Q4","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nNDL6b0fYP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","LU2210150020.SGD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014005.SGD","BK4112","LU0314104364.USD","BK4588","NDAQ","SG9999014039.USD","PHAT","BK4007","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","LU2210149790.SGD","SG9999014013.SGD"],"gpt_icon":0},{"id":"2614804591","title":"Phathom Pharmaceuticals Q4 Adj. EPS $(0.08) Beats $(0.38) Estimate, Sales $57.584M Beat $57.050M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2614804591","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614804591?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:01","pubTimestamp":1772107291,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals (NASDAQ:PHAT) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.38) by 79 percent. This is a 89.87 percent increase over losses of $(0.79) per share","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/02/50881899/phathom-pharmaceuticals-q4-adj-eps-0-08-beats-0-38-estimate-sales-57-584m-beat-57-050m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT"],"gpt_icon":0},{"id":"2614045451","title":"BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045451","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045451?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107251,"startTime":"0","endTime":"0","summary":"BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -21.148 Million\n\n\nFeb 26 (Reuters) - Phathom Pharmaceuticals Q4 revenue USD 57.584 million vs. IBES estimate USD 57 million.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX681997:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2614046683","title":"Phathom Pharmaceuticals Inc Outlook 2026 Net Revenues of $320-$345 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046683","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046683?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107207,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX681997:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2614046542","title":"Phathom Pharmaceuticals Inc: Operating Profitability Expected Beginning in Q3 2026 and for FY 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2614046542","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614046542?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107207,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260226:nPLX681997:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2614045407","title":"Press Release: Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Financial Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=2614045407","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614045407?lang=en_us&edition=fundamental","pubTime":"2026-02-26 20:00","pubTimestamp":1772107200,"startTime":"0","endTime":"0","summary":"-- Over 1.1 million total VOQUEZNA prescriptions filled to date. -- $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues,-- Q4 operating expenses of $55.9 million; non-GAAP operating expenses of. $50.3 million and net cash usage of approximately $5.2 million,-- Strengthened financial position through $130 million equity offering and. -- Providing FY 2026 guidance; operating profitability expected beginning in. -- Management to host conference call today, February 26, 2026, at 8:00 a.m.\"Phathom exited 2025 with strong revenue growth and meaningful progress on expense discipline initiatives,\" said Sanjeev Narula, Chief Financial and Business Officer of Phathom. \"Following our January financing, we negotiated a modification to our term loan to reduce interest and extend maturity. We believe these steps provide us with an enhanced capital structure and financial flexibility as we position Phathom for anticipated operating profitability beginning in the third quarter 202","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["R","BK4007","BK4232","BK4022","PHAT"],"gpt_icon":0},{"id":"2613782480","title":"Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2613782480","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613782480?lang=en_us&edition=fundamental","pubTime":"2026-02-23 21:00","pubTimestamp":1771851600,"startTime":"0","endTime":"0","summary":"FLORHAM PARK, N.J., Feb.  23, 2026  (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/02/23/3242577/0/en/Phathom-Pharmaceuticals-to-Participate-in-Upcoming-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2612452655","title":"Phathom Pharmaceuticals Inc. to Report Financial Results and Provide Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2612452655","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2612452655?lang=en_us&edition=fundamental","pubTime":"2026-02-17 21:01","pubTimestamp":1771333304,"startTime":"0","endTime":"0","summary":"Phathom Pharmaceuticals Inc. will report its fourth quarter and full year 2025 financial results and provide a business update on Thursday, February 26, 2026. Management will host a live webcast conference call at 8:00 am EST, which can be accessed on the Events & Presentations section of the Phathom website at Events & Presentations. A recording will be available for 90 days following the call.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire  on February 17, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nNDL1J4Yd0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2095319765.USD","SG9999014013.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","PHAT","SG9999014021.USD","BK4007","NDAQ","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","BK4585","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2605945564","title":"Analysts Offer Insights on Healthcare Companies: Oscar Health (OSCR) and Phathom Pharmaceuticals (PHAT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605945564","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605945564?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:30","pubTimestamp":1769088609,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oscar Health (OSCR – Research Report) and Phathom ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oscar-health-oscr-and-phathom-pharmaceuticals-phat-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-oscar-health-oscr-and-phathom-pharmaceuticals-phat-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBI","LU0029874061.USD","LU0128526141.USD","OSCR","BK4588","PHAT","BK4581","LABU","BK4585","BK4162","BK4551","BK4007","BK4137"],"gpt_icon":0},{"id":"2602539538","title":"Assessing Phathom Pharmaceuticals (PHAT) Valuation After Recent Share Price Volatility","url":"https://stock-news.laohu8.com/highlight/detail?id=2602539538","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602539538?lang=en_us&edition=fundamental","pubTime":"2026-01-11 03:16","pubTimestamp":1768072618,"startTime":"0","endTime":"0","summary":"What recent performance says about Phathom Pharmaceuticals\nWithout a single clear news catalyst, Phathom Pharmaceuticals (PHAT) has still drawn attention after a recent month of modest gains, a stronger move over the past 3 months, and a sharply positive 1 year total return.\nThose returns sit against a value score of 4 and a share price of about $15.02 at the last close. This has prompted some investors to compare that recent performance with the company’s current fundamentals.\nSee our latest...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/assessing-phathom-pharmaceuticals-phat-valuation-after-recen","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-phat/phathom-pharmaceuticals/news/assessing-phathom-pharmaceuticals-phat-valuation-after-recen","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","PHAT"],"gpt_icon":0},{"id":"2602731392","title":"Phathom Pharmaceuticals Announces $130 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2602731392","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602731392?lang=en_us&edition=fundamental","pubTime":"2026-01-09 05:36","pubTimestamp":1767908161,"startTime":"0","endTime":"0","summary":"An update from Phathom Pharmaceuticals ( ($PHAT) ) is now available. On January 7, 2026, Phathom Pharmaceuticals entered into an underwriting agree...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-announces-130-million-public-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/phathom-pharmaceuticals-announces-130-million-public-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PHAT","BK4007"],"gpt_icon":0},{"id":"2601958623","title":"Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), InMode (INMD) and Bristol-Myers Squibb (BMY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2601958623","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601958623?lang=en_us&edition=fundamental","pubTime":"2026-01-08 23:01","pubTimestamp":1767884460,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Phathom Pharmaceuticals (PHAT – Research Report), InMode (INMD – ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-inmode-inmd-and-bristol-myers-squibb-bmy-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-phathom-pharmaceuticals-phat-inmode-inmd-and-bristol-myers-squibb-bmy-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1261432733.SGD","XBI","BK4534","LU0868494617.USD","LU1868836914.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU0225284248.USD","LU0061475181.USD","XLV","LU1868836591.USD","LABU","LU0882574055.USD","BK4532","LU1323610961.USD","IE00B2B36J28.USD","LU1430594728.SGD","BK4588","LU2125154935.USD","LU0114720955.EUR","IE00BJT1NW94.SGD","BK4082","LU1032466523.USD","LU1868837300.USD","LU1718418525.SGD","IE00BSNM7G36.USD","LU0321505439.SGD","LU1291159041.SGD","PHAT","LU1989771016.USD","LU0128526141.USD","LU2125154778.USD","BK4559","IE00BFXG1179.USD","LU1093756325.SGD","LU1670711123.USD","LU1670710588.SGD","HCSG","LU1868836757.USD","INMD","BMY","IE0009355771.USD","LU0029874061.USD","LU2360032135.SGD","BK4007","LU1585245621.USD","LU0306806265.USD","LU2133065610.SGD","LU1670710661.SGD","LU0225771236.USD"],"gpt_icon":0},{"id":"2601360407","title":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, Nike","url":"https://stock-news.laohu8.com/highlight/detail?id=2601360407","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601360407?lang=en_us&edition=fundamental","pubTime":"2026-01-08 22:21","pubTimestamp":1767882071,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-Sigma Lithium, Darden Restaurants, NikeEikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsle","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nL6N3Y90NJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LNN","BW","GM","SCCO","TFX","LU0868494708.USD","VLO","89988","HOUS","BK4596","HL","TYL","KTOS","NEM","COMP","MLTX","LU1267930227.SGD","HELE","JCAP","MPC","IE00B4R5TH58.HKD","NOC","ALBmain","GLUE","DRI","LU0396098781.USD","NEOG","NKE","SHOO","F","RTX","HBBD.SI","LU2097828805.USD","PHAT","CDE","AA","RVMD","LU0577902298.EUR","STZ","VNDA","ABBV","APD"],"gpt_icon":1},{"id":"2601013364","title":"Immuneering, Phathom Pharmaceuticals, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session","url":"https://stock-news.laohu8.com/highlight/detail?id=2601013364","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601013364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:06","pubTimestamp":1767877560,"startTime":"0","endTime":"0","summary":"U.S. stock futures were lower this morning, with the Dow futures falling more than 100 points on Thursday.Shares of Immuneering Corp  fell sharply in pre-market trading.The company announced updated overall survival and safety data from its ongoing Phase 2a trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients, with over 13 months median follow up time.Immuneering shares dipped 20.7% to $6.61 in pre-market trading.Here are some other stocks moving lower in pre-market trading.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/08/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/08/Display-Of-Stock-Market-Quotes.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/trading-ideas/movers/26/01/49780387/immuneering-phathom-pharmaceuticals-canadian-solar-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/26/01/49780387/immuneering-phathom-pharmaceuticals-canadian-solar-and-other-big-stocks-moving-lower-in-thursdays-pre-market-session","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4141","BK4585","PHAT","BK4139","BK4588","BK4526","BK4539","IMRX","BK4519","BK4007","BK4563"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.phathompharma.com","stockEarnings":[{"period":"1week","weight":0.0998},{"period":"1month","weight":-0.0925},{"period":"3month","weight":-0.1959},{"period":"6month","weight":0.0312},{"period":"1year","weight":1.1806},{"period":"ytd","weight":-0.2429}],"compareEarnings":[{"period":"1week","weight":-0.005},{"period":"1month","weight":-0.0136},{"period":"3month","weight":0.0038},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1725},{"period":"ytd","weight":0.006}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.079508},{"month":2,"riseRate":0.571429,"avgChangeRate":0.0658},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.119883},{"month":4,"riseRate":0.5,"avgChangeRate":0.053339},{"month":5,"riseRate":0.5,"avgChangeRate":-0.02431},{"month":6,"riseRate":0.666667,"avgChangeRate":0.246775},{"month":7,"riseRate":0.666667,"avgChangeRate":0.025067},{"month":8,"riseRate":0.666667,"avgChangeRate":0.15186},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.003613},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.040055},{"month":11,"riseRate":0.428571,"avgChangeRate":-0.100392},{"month":12,"riseRate":0.714286,"avgChangeRate":0.070942}],"exchange":"NASDAQ","name":"Phathom Pharmaceuticals","nameEN":"Phathom Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Phathom Pharmaceuticals,PHAT,Phathom Pharmaceuticals股票,Phathom Pharmaceuticals股票老虎,Phathom Pharmaceuticals股票老虎国际,Phathom Pharmaceuticals行情,Phathom Pharmaceuticals股票行情,Phathom Pharmaceuticals股价,Phathom Pharmaceuticals股市,Phathom Pharmaceuticals股票价格,Phathom Pharmaceuticals股票交易,Phathom Pharmaceuticals股票购买,Phathom Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Phathom Pharmaceuticals(PHAT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Phathom Pharmaceuticals(PHAT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}